BidaskClub lowered shares of TherapeuticsMD Inc (NYSEMKT:TXMD) from a hold rating to a sell rating in a report published on Wednesday morning.

TXMD has been the subject of a number of other reports. Oppenheimer Holdings, Inc. upgraded TherapeuticsMD from a market perform rating to an outperform rating in a research note on Tuesday, July 11th. Morgan Stanley began coverage on TherapeuticsMD in a research note on Friday, September 8th. They set an equal weight rating and a $6.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $18.93.

Shares of TherapeuticsMD (TXMD) opened at 5.29 on Wednesday. The company’s 50 day moving average price is $6.02 and its 200 day moving average price is $5.58. The firm’s market capitalization is $1.08 billion. TherapeuticsMD has a one year low of $3.50 and a one year high of $8.30.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD Inc (TXMD) Cut to “Sell” at BidaskClub” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.